Home » Xoma Expands Development Strategy for Xoma 052
Xoma Expands Development Strategy for Xoma 052
XOMA Ltd. announced the expansion of its development strategy for its XOMA 052 antibody to interleukin-1 beta to include effects on cholesterol lowering,
reducing plaque deposits and damage to heart muscle and resulting long-term effects that can lead to heart attack, stroke and congestive heart failure.
CNNMoney
CNNMoney
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May